A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
NCT07225712
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
SEP-363856
Sponsor
Otsuka Pharmaceutical Co., Ltd.